Long-term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients
| Autor: | Silvia Ferrucci, Simona Tavecchio, L Bonzano, Luigi Macchia, Giulia Calabrese, Maddalena Napolitano, Steven Paul Nisticò, Caterina Foti, Aikaterini Detoraki, Katharina Hansel, Giuseppe Argenziano, Giovanni Pellacani, Paolo Romita, Michela Ortoncelli, Franco Rongioletti, Luca Stingeni, E. Di Leo, Gabriella Fabbrocini, Simone Ribero, M Carbonara, Cataldo Patruno, Eustachio Nettis, Viviana Piras, Danilo Di Bona |
|---|---|
| Přispěvatelé: | Nettis, E, Fabbrocini, G, Ortoncelli, M, Pellacani, G, Argenziano, G, Di Leo, E, Patruno, C, Stingeni, L, Foti, C, Rongioletti, F, Macchia, L, Tavecchio, S, Napolitano, M, Ribero, S, Bonzano, L, Calabrese, G, Di Bona, D, Nisticò, S P, Hansel, K, Romita, P, Piras, V, Carbonara, M, Detoraki, A, Ferrucci, S M, Nettis, E., Fabbrocini, G., Ortoncelli, M., Pellacani, G., Argenziano, G., Di Leo, E., Patruno, C., Stingeni, L., Foti, C., Rongioletti, F., Macchia, L., Tavecchio, S., Napolitano, M., Ribero, S., Bonzano, L., Calabrese, G., Di Bona, D., Nistico, S. P., Hansel, K., Romita, P., Piras, V., Carbonara, M., Detoraki, A., Ferrucci, S. M. |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
medicine.medical_specialty Adult patients business.industry Eczema Interleukin Dermatology Atopic dermatitis medicine.disease Antibodies Monoclonal Humanized Dupilumab Dermatitis Atopic 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Monoclonal Medicine Humans business |
| Popis: | Dupilumab, an inhibitor of interleukin (IL)-4/13 activity, is a biological agent approved for the treatment of moderate-to-severe atopic dermatitis (AD)1 . Our aim was to assess the long-term effectiveness and safety of dupilumab in a clinical real-life setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|